Actively Recruiting
Evaluation of an Intervention to Reduce Smoking Among Mental Health Users Treated in Ambulatory Psychiatry
Led by GCS-CCOMS · Updated on 2026-02-02
6500
Participants Needed
22
Research Sites
26 weeks
Total Duration
On this page
Sponsors
G
GCS-CCOMS
Lead Sponsor
I
INSERM ECEVE 1123
Collaborating Sponsor
AI-Summary
What this Trial Is About
People with mental disorders tend to smoke more than the general population, which contributes to a significant reduction in their life expectancy by 10 to 20 years, mainly due to heart and lung diseases such as bronchial cancers. Despite this, smoking cessation efforts tailored for psychiatric patients are limited, as smoking is often overlooked or accepted in mental health care settings. This study aims to assess a smoking cessation program called Tabapsy designed with input from mental health users, professionals, and general practitioners, focusing on adult patients receiving outpatient psychiatric care. The Tabapsy intervention includes a campaign promoting smoking cessation within psychiatric medical psychological centers CMPs and a series of supportive activities. These activities involve an initial information meeting to boost motivation, an assessment workshop to evaluate nicotine dependence and create personalized quitting plans, five thematic workshops covering nicotine replacement, emotional management, weight control, physical activity, and manual tasks, and peer support groups for shared experiences. A dedicated facilitator will lead these sessions, supported by an online resource website. The study compares the intervention against usual care in a national cluster-randomized trial involving psychiatric sectors. Participants who smoke regularly and consent will complete questionnaires via a web app at the start, 3 months, and 6 months, with additional surveys for those in the intervention group. The questionnaires cover smoking habits, dependence, motivation, cessation aid use, mental and physical well-being, and knowledge about tobacco. The main outcome is smoking cessation lasting at least 7 days at 3 months. Secondary outcomes include cost-effectiveness, implementation, quit attempts, and satisfaction. A total of 6,250 participants will be enrolled over 12 months across 22 sectors.
CONDITIONS
Brief Title
Interventional Study on Smoking Reduction in Psychiatry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Regular smokers (at least one cigarette per day)
- Adults aged 18 years or older
- Receiving outpatient psychiatric care at a participating medical psychological center
- Covered by statutory health insurance
- Provided informed consent to participate in the study
You will not qualify if you...
- Under guardianship or legal protection
- Psychological state prevents completing questionnaires
- Does not understand or speak French sufficiently to complete questionnaires
Research Team
J
Jean-Luc ROELANDT, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here